Hypertension in young adults and exploring its role in sudden cardiac death: expert opinion from India

INTRODUCTION

Hypertension, or high blood pressure (BP), affects 1 in 3 adults worldwide, and if left untreated, may lead to stroke, myocardial infarction (MI), heart failure (HF), and kidney dysfunction. The number of people affected by hypertension (BP of 140/90 mmHg or higher or taking medication for hypertension) doubled between 1990 and 2019 (650 million to 1.3 billion), and around 50% of them are unaware of their condition.¹ More than 75% of adults with hypertension belong to low- and middle-income countries.¹ According to the Fifth National Family Health Survey (NFHS-5), hypertension is a predominant risk factor for death and disability in India.²

A narrative review by Gupta et al on hypertension prevalence and control in India reported a high prevalence of young-age hypertension, predominantly in the less developed states.³ The NFHS-5 and the ICMR-India DIABetes (INDIAB) studies have reported considerable geographic variations in hypertension prevalence in India. Notably, in India the incidence of hypertension-related cardiovascular disease is significantly higher compared to more developed countries.³

Every year millions of young individuals, not only in India but around the world, die suddenly in the prime of their lives, with the prior to majority of deaths being attributable to sudden cardiac death (SCD).⁴ SCD leaves no opportunity to revive or treat the patient as it usually occurs outside hospital settings.⁴ Globally the incidence of SCD is 0.03%–0.10% per year, translating to >2 million deaths annually, most of them happening in young individuals.⁵ SCD also accounts for over 60% of cardiovascular deaths.⁶ While the understanding of the underlying pathophysiology and causes of SCD is currently evolving, age, hypertension, smoking, diabetes mellitus (DM), dyslipidemia, obesity, and family history are considered some of the important risk factors.^4,6

With the rising incidence of hypertension in young individuals in India, it is important to explore whether hypertension plays an important role in the incidence of SCD. Some studies have pointed towards the link between hypertension and SCD, but further studies and insights from experienced cardiologists will be valuable in this aspect and will help in designing an infallible strategy to prevent SCD in India.^7,8

Despite the availability of several antihypertensive drugs, effective hypertension management in a resource-limited country like India is challenging due to factors such as low levels of awareness, inadequate screening, and a lack optimal healthcare facilities, especially in rural and some urban areas. This expert opinion paper provides a comprehensive evaluation of the current situation of hypertension prevalence, diagnosis, and challenges in treatment, with a focus on young Indian adults.

Moreover, it delves into the possible causes of the increasing incidence of SCD, its risk factors, diagnosis, and prevention strategies, especially in young adults with hypertension. This paper also helps in leveraging insights from expert cardiologists on the use of fixed-dose combinations (FDCs; particularly angiotensin II receptor blockers [ARBs] and β-blockers), highlighting their potential positioning amongst the existing armamentarium against hypertension in India.

METHODS

The methodology for creating this expert opinion paper involved a multidisciplinary panel of cardiologists from across India to discuss the treatment approach for hypertension and SCD in young adults with hypertension. The meetings were moderated by experienced cardiologists. The experts discussed the following aspects, particularly with a focus on young hypertensives: increase in incidence, risk factors, challenges in controlling hypertension, screening, diagnosis, and management of hypertension and its possible role in SCD.

The insights from the meetings were collated in this expert opinion, which was reviewed and endorsed by some of the expert panelists who are the authors of this article.

These insights are further supported by recent literature available on hypertension and SCD.

WHAT SHOULD BE THE AGE CUT-OFF FOR DEFINING YOUNG HYPERTENSIVES IN INDIA?

Clinical evidence

The National Institute for Health and Care Excellence (NICE) guidelines and the European Society of Cardiology/European Society of Hypertension (ESC/ESH) guidelines typically consider young-onset hypertension as hypertension diagnosed before the age of 40.^9,10 The American College of Cardiology/American Heart Association (ACC/AHA) guidelines do not assign a strict age cutoff for defining “young hypertensives,” instead, they consider a risk-based strategy for treatment decisions.¹¹

In the Indian hypertension guidelines (IGH IV), young hypertensives are generally considered to be individuals <55 years of age.¹² Hypertension prevalence in the age group <30 years was higher in India compared to central and eastern Europe, high-income Western world and other South Asian countries.

Expert opinion

In line with most international guidelines, some panelists considered <40 years as the good age cut-off for defining hypertensive young adults in India. However, the majority of the experts believed that in India the patients get affected by diseases a decade earlier than in the Western countries. Therefore, the Indian age cut-off should be reduced by 10 years and include patients <30 years. With this age cut-off, more young patients can be classified as hypertensives and initiated on pharmacotherapy for the prevention of coronary artery disease (CAD) and SCD (which also affected Indian patients a decade earlier).

WHAT IS THE BURDEN OF HYPERTENSIVE YOUNG ADULTS IN INDIA?

Clinical evidence

Overall prevalence of hypertension is significantly high (300–320 million) in India.¹³ The burden of hypertension is further complicated as there are marked disparities in awareness, diagnosis, treatment, and control rates across different regions and socio-demographic groups. Recent studies have shown that there is an increase in the incidence of hypertension in India, more notably in the rural population (25-35% in urban versus 15-20% rural). The prevalence in young and elderly individuals is 10.8% and 41.9%, respectively, whereas the prevalence in men and women is 24% and 21%, respectively.^2,3

There is a higher prevalence of young-age hypertension, especially in the less developed states.³ A study also found a comparatively higher prevalence among the youngest age group sampled (9.6% [95% CI 9.3–9.9%] among those aged 15 to 29 years).

Expert opinion

Key insights from the experts on the burden of hypertension in India are enlisted in Table 1.

WHAT IS THE PATIENT JOURNEY AND RISK FACTORS ASSOCIATED WITH HYPERTENSION IN YOUNG ADULTS?

Clinical evidence

Individuals with hypertension often experience challenges due to various contributing factors such as limited awareness of their condition, self-medication practices, physical distance to health facilities, availability of social support, high out-of-pocket expenditure, availability of medicines, and pill burden. Some patients use self-medication, including traditional herbal remedies, in Indian healthcare. While young adults largely from low socioeconomic backgrounds recognized hypertension as a lifelong disease, only older individuals were committed to medication adherence.¹⁴

There are several risk factors associated with hypertension. The non-modifiable risk factors include age, family history, genetic predisposition, sex, race, and ethnicity.¹⁵ Important modifiable risk factors are obesity, diabetes, diet, physical activity, stress, alcohol, and tobacco use. Poor dietary habits such as high salt intake and low potassium intake are also linked to hypertension.¹⁶ Obstructive sleep apnea (OSA) is one of the important risk factors associated with hypertension. It is hypothesized that OSA and hypertension are comorbid conditions that have adversely related pathophysiology, including sympathetic hyperactivity, endothelial damage, and gut dysbiosis. Young adults who have hypertension of unknown etiology are susceptible to OSA.¹⁷

Hypertension in young adults is linked to an increased risk of cardiovascular (CV) events in middle age.¹⁸ Hypertension, if left untreated, is also associated with an earlier onset of coronary heart disease (CHD), HF, stroke, transient ischemic attacks, kidney dysfunction and/or end-organ damage.¹⁹ Two recent Indian studies, NFHS-4 and the Longitudinal Aging Study in India (LASI) reported low rates of hypertension awareness, treatment and control with significantly lower rates in the young adults compared to the older individuals.^20,21

Expert opinion

Risk factors for hypertension that are more commonly associated with young males are smoking and alcohol use. In females an important risk factor is polycystic ovarian disease (PCOD). Sedentary lifestyle, stress, unhealthy diet (rich in sodium), and obesity are some other common risk factors in young adults (Table 2). Complications in hypertensive young adults may not start early, and only 20% may have complications before they reach their 40s. Most hypertensive young adults are diagnosed during routine checkups, job fitness exams, or insurance screenings. They usually remain asymptomatic at the time of diagnosis. Life-threatening complications can occur even at stage 1 of HTN; of which the important complications are STEMI and acute coronary syndrome (ACS). The typical patient journey of hypertensive young adults can be summarized in Figure 1.

DM: Diabetes mellitus, STEMI: ST-elevation myocardial infarction.

WHAT IS THE PATHOPHYSIOLOGY OF HYPERTENSION IN YOUNG ADULTS AND THE KEY DIFFERENCES COMPARED TO OLDER ADULTS?

Clinical evidence

Hypertension, especially in young adults, along with its related cardiovascular disorders is linked to sympathetic overactivity.²² In hypertension the higher sympathetic tone is linked to insulin resistance and dyslipidemia. Several mechanisms exist through which sympathetic overactivity possibly causes both hypertension and metabolic syndrome.²³ In India, around 60% of newly diagnosed hypertensive patients have sympathetic overactivity. Symptoms such as restlessness, excessive sweating, and hand tremors are indicators of sympathetic overactivity and should be taken into account while treating patients (especially young adults) with hypertension.^22,24 Apart from sympathetic overactivity, a complex interplay of various elements of an integrated neurohumoral system, such as the renin-angiotensin-aldosterone system (RAAS), natriuretic peptides, and the immune system is involved in maintaining homeostatic BP levels. Other contributing factors are endothelial dysfunction and arterial stiffness.²⁵

Expert opinion

In young adults, hypertension is driven by sympathetic overactivity and endothelial dysfunction. These individuals often have increased heart rate and peripheral resistance. Smoking coupled with a sedentary lifestyle worsens endothelial damage, making hypertension more likely. Unlike in the elderly, arterial stiffness is not a major factor for hypertension in the young. Factors associated with the underlying pathophysiology of hypertension in young adults and some of the key differences from older adults are enlisted in Table 3.

WHAT ARE THE RISK FACTORS OF SUDDEN CARDIAC DEATH, AND THE ROLE OF HYPERTENSION IN SCD?

Clinical evidence

Age, hypertension, dyslipidemia, obesity, smoking, DM, and family history are considered the main risk factors for SCD. Studies have indicated that elevated BP and hypertension are linked to increased risk of SCD.^7,8,26 The lifetime risk of SCD at the age of 30 is higher in 30% of individuals with hypertension. Further, a 20/10 mm Hg increase in systolic/diastolic BP is linked to an additional 20% increase in the risk of SCD.²⁷A meta-analysis has shown an increased risk of SCD with the diagnosis of hypertension and increasing systolic BP (SBP) with a nonlinear relationship between SCD and SBP.⁷ In patients with hypertension without cardiovascular disease, age, DM, electrocardiography (ECG) left ventricular hypertrophy (LVH), and 24-hour ambulatory pulse pressure are identified as independent long-term prognostic markers for SCD. Acute left ventricular heart failure (LVHF) is one of the common causes of SCD as a result of hypertension.⁸

In Western countries, CAD is a major risk factor of SCD, however, studies linking CAD to SCD in South Asian countries are lacking.²⁸ Around 60% of the world's CAD patients are South Asians, and CAD risk factors are present in them from a relatively young age.²⁹ The Indian SCD cohort includes predominantly men of relatively young age, which is clearly a distinction from the West which includes older men.^30-32 Other causes of SCD, especially in the younger population are myocarditis and endocarditis, cardiomyopathies, valvular heart disease, conduction system anomalies, cardiac tumors, aortic disease rupture, Brugada syndrome, and channelopathies. The main cause of SCD in the elderly is CAD or HF.³³

Risk stratification for SCD during follow-up should be individualized. A recent meta-analysis showed a high risk of long-term recurrence (41%) of ventricular arrhythmias and identified presentation with monomorphic ventricular tachycardia as a marker of poor prognosis. A recent review recommends community-based ECG screening once during school age and again during college age as a preventive measure against SCD (Figure 2).⁴

Expert opinion

LVH can cause abnormal signaling in heart, which in turn may lead to hypertension. Thus, LVH is one of the possible factors that may be a common link between hypertension with SCD. Markers such as C-reactive protein (CRP), lipoprotein a/Lp (a) are some of the markers that can be considered as predictors of atherosclerotic cardiovascular disease (ASCVD)/SCD. Further studies, especially in young adults from India are needed to corroborate it further. Opinion from experts on the investigations that can be used in clinical practice for prediction of SCD in India, and proposed algorithm for prevention of SCD in young hypertensives in India are given in Table 4 and Figure 3, respectively.

HOW SHOULD YOUNG ADULTS BE DIAGNOSED/SCREENED FOR HYPERTENSION AND WHAT ARE THE FACTORS DELAYING DIAGNOSIS IN YOUNG ADULTS?

Clinical evidence

Hypertension guidelines do not differentiate between screening and diagnosis of young and older adults (Table 5). Office BP monitoring (OBPM), Home BP monitoring (HBPM), and Ambulatory BP monitoring (ABPM) should be done as per standard guidelines such as ESC/ESH Guidelines.³⁴ Some of the important biomarkers for hypertension onset are serum lipids (LDL and VLDL-derived cholesterol levels) and glucose metabolism abnormalities. The European Atherosclerosis Society (EAS) consensus (2022) recommends Lp(a) test at least once in lifetime for adults.³⁵

Expert opinion

In India, the diagnosis of hypertension is primarily based on OBPM as it is the most accessible and widely used method. HBPM and ABPM are ideal, but they are used only for selected individuals. In clinical settings, BP is often measured once by either the doctor or nurse, but ideally, it should be measured multiple times (at least three measurements with one-minute intervals) to obtain an accurate reading. However, this practice may not always be followed consistently across all settings. Key insights from experts on the diagnosis and screening of hypertension in young adults are enlisted in Table 6. Some of the factors responsible for delay in the diagnosis of hypertension in young adults are given in Figure 4.

WHAT SHOULD BE THE TREATMENT STRATEGY FOR HYPERTENSIVE YOUNG ADULTS?

Clinical evidence

ESC/ESH Guidelines (2024) do not recommend different treatment strategies for the management of hypertension in young and older adults (Figure 5A).³⁴ However, the Indian Guidelines on Hypertension IV (IGH IV) recommend different treatment strategies for younger and older patients with hypertension (Figure 5B).³⁶ The Indian Guidelines recommend the use of angiotensin-converting enzyme inhibitors (ACEis) or ARBs or newer β-blockers for younger individuals. These guidelines also recommend the use of newer β-blockers in hypertensive young adults in special situations, such as angina, post-MI, tachyarrhythmia, or HF.

Guidelines, including the ESC/ESH and Indian guidelines on hypertension-IV (2019), recommend the use of ACEi or ARBs as a first-line therapy for hypertension (Figure 5).^34,36 β-blockers can be vital in managing hypertension in young adults due to sympathetic overactivity that is associated with the development of hypertension especially in young adults in India.²⁴ ARBs are better tolerated by patients compared to the other major anti-hypertensive classes of drugs. Cardiovascular protective effects of ACEis and ARBs are rather similar, but compared with other agents, ARBs may offer better protection against stroke.³⁷ FDCs have been recommended by most of the hypertension management guidelines due to the potential of increasing patient compliance and convenience while achieving better BP control.³⁸ Several studies have supported the use of a combination of ARBs and β-blockers in the effective management of hypertension in Indian patients, especially in hypertensive young adults. An Indian cross-sectional study has shown that clinicians prefer a combination of ARBs and β-blockers as the first-line treatment for managing hypertension in young adults. β-blockers are the drug of choice, mainly due to their ability to manage sympathetic overactivity that is largely found in this population.³⁹

A recent study on identifying drug prescription patterns for newly diagnosed hypertension patients in India, showed that ARBs were the most commonly prescribed drugs (79%), followed by calcium channel blockers (CCBs; 55%) diuretics (27%) and β‐blockers (17%).⁴⁰ This suggests a need for better awareness of β-blockers, as these should be preferred for newly diagnosed young patients with hypertension, especially those with an increased HR.

Expert opinion

Key insights from experts on the use of ARBs and β-blockers for hypertensive young adults are enlisted in Table 7.

WHAT ARE THE ADVANTAGES OF BISOPROLOL AND TELMISARTAN FDC?

Clinical evidence

An open-label, phase IV, multicentre, prospective study has shown that bisoprolol was efficacious in stage 1 hypertension in Indian adults, it significantly reduced SBP, DBP, and HR. Further, the combination of telmisartan + bisoprolol significantly reduced SBP in younger adults compared to telmisartan + metoprolol.⁴¹ Additional benefits of bisoprolol in some other conditions such as CAD, chronic obstructive pulmonary disease (COPD), LVH and HF are enlisted in Table 8.^39,42-44 The FDC of telmisartan + bisoprolol has shown superiority over the combination of telmisartan + metoprolol FDC in effectively controlling SBP in young patients. This combination has demonstrated effectiveness in the management of hypertension, along with benefits such as reducing cardiovascular risk and improving organ function.⁴⁵ A phase 3 multicentric clinical trial has established the efficacy, tolerability, and safety of the FDC of telmisartan 40 mg + bisoprolol 5 mg for the management of stage 1 and stage 2 hypertension.⁴⁶

Expert opinion

Telmisartan is the most preferred ARB in India due to its high potency for blocking AT1 receptors and its long-acting effects, with a duration of almost 24 hours. Telmisartan also has the added benefit of peroxisome proliferator-activated receptor (PPAR) gamma activity, which can help reduce blood sugar levels in diabetic patients. It has OD dosing and is well tolerated. Bisoprolol is the most preferred β-blocker due to advantages such as cardio-selectivity, ease of dosing (up to 10 mg, OD), better pulsatory reduction and atopic reduction, pleiotropic effects in COPD, exercise tolerance, and prevention of SCD and MI.

Telmisartan + bisoprolol is a welcome combination which has been useful in the management of hypertension in young adults. Bisoprolol helps in reducing ventricular arrhythmias, ventricular premature beats (VPDs), and lowers the risk of SCD, making it an ideal choice. Together, telmisartan and bisoprolol provide comprehensive cardiovascular protection, addressing both hypertension and arrhythmic risks. Some key insights on the rationality of using the combination of telmisartan + bisoprolol are given in Table 9.

AVD: Arrhythmogenic ventricular disorder; ECG: electrocardiography; ECHO: echocardiography; LQTS: long QT syndrome; LVH: left ventricular hypertrophy; SCD: sudden cardiac death.

HTN: Hypertension; RAAS: renin-angiotensin-aldosterone system; SCD: sudden cardiac death

CT: Computed tomography; ECG: electrocardiography; GEH: global electrical heterogeneity; GLS: global longitudinal strain; Lp(a): lipoprotein(a); LVH: left ventricular hypertrophy; MI: myocardial infarction; MR: magnetic resonance; SCD: sudden cardiac death; SVG: spatial ventricular gradient

BMI: Body mass index; CRP: C-reactive protein; CKD: chronic kidney disease; CT: computed tomography; CVD: cardiovascular disease; ECG: electrocardiography; eGFR: estimated glomerular filtration rate; HTN: hypertension; HMOD: hypertension mediated organ damage; KFT: kidney function test; Lp(a): lipoprotein a; MRI: magnetic resonance imaging

CRP: C-reactive protein; CT: computed tomography; HTN: hypertension; KFT: kidney function test; Lp(a): lipoprotein(a)

ASCVD: Arrhythmogenic ventricular disorder; BP: blood pressure; ECG: electrocardiography; ECHO: echocardiography; HCM: hypertrophic cardiomyopathy; LQTS: long QT syndrome; LVH: left ventricular hypertrophy; LVEF: left ventricular ejection fraction; MRI: magnetic resonance imaging; SCD: sudden cardiac death

ACEi: Angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; BP: blood pressure; CCB: calcium channel blocker; CV: cardiovascular; MRA: mineralocorticoid receptor antagonist; mmHg: millimetres of mercury

ARB: Angiotensin II receptor blocker; β-blockers: beta blockers; BP: blood pressure; HR: heart rate.

BP: Blood pressure; COPD: chronic obstructive pulmonary disease; LVH: left ventricular hypertrophy; SCD: sudden cardiac death; VF: ventricular fibrillation; VT: ventricular tachycardia

ARB: Angiotensin II receptor blocker; BP: blood pressure; COPD: chronic obstructive pulmonary disorder; CV: cardiovascular; HR: heart rate

CONCLUSION

The incidence of hypertension in young adults is rapidly increasing in India owing to lifestyle and environmental factors such as obesity, and stress. It is one of the key public health concerns for adults even below the age of 40. Initiation of an early and appropriate antihypertensive treatment in this population is important to avoid vascular and organ damage. However, age-specific recommendations for managing hypertension in young adults are lacking, as current guidelines often extrapolate from older cohorts. There is also a lack of evidence from randomized trials to guide pharmacotherapy in young adults who have a low 10-year ASCVD risk. This expert opinion paper tries to bridge this gap by defining the age cut-off for young adults with hypertension, and identifying unique lifestyle factors in the young adults, such as obesity, diet rich in sodium, sedentary lifestyle, increased stress, and alcohol/tobacco consumption as the main contributors for the increasing incidence of hypertension in this population. Sympathetic overactivity is considered as one of the key contributors of hypertension in young adults supporting the use of ARBs and beta blockers as one of the preferred classes of anti-hypertensive drugs, especially in the cases of resistant hypertension or in young adults with comorbidities. The experts also indicated that the FDC of telmisartan and a cardio-selective β-blocker such as bisoprolol can be an ideal antihypertensive treatment. Uncontrolled hypertension is also identified as one of the possible risk factors of SCD. The FDC of Telmisartan and bisoprolol is effective in treating hypertension in young and may also help in preventing SCD. Additionally, this FDC is cost-effective and reduces the pill burden (a known cause of lack of adherence to anti-hypertensive medication), enabling patients to continue long-term treatment.

ACKNOWLEDGEMENTS

Authors would like to acknowledge the contribution of experts across India who gave their expert opinion in conceptualization and finalization of this expert opinion paper. The authors thank Latika Saxena, PhD, and Dr. Sujatha Vijayakumar of Hashtag Medical Writing Solutions Pvt Ltd, Chennai, India for providing medical writing and editorial support, which was funded by Abbott India Ltd, Mumbai, India in accordance with Good Publication Practice (GPP3) guidelines.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

1. 1. World Health Organization. First WHO report details devastating impact of hypertension and ways to stop it. 2023. Available at: https://www.who.int/news/item/19-09-2023-first-who-report-details-devastating-impact-of-hypertension-and-ways-to-stop-it. Accessed on 21 May 2026.
2. 2. National Family Health Survey (Nfhs-5) 2019–21. Available at: https://dhsprogram.com/pubs/pdf/FR375/FR375.pdf. Accessed on 21 May 2026.
3. 3. Gupta R, Gaur K, Ahuja S, Anjana RM. Recent studies on hypertension prevalence and control in India 2023. Hypertens Res. 2024;47(6):1445-56.
4. 4. Premanath M. Sudden Cardiac Death – Can it be Prevented? APIK J Internal Med. 2024;12:250-2.
5. 5. Ha ACT, Doumouras BS, Wang C (Nancy), Tranmer J, Lee DS. Prediction of Sudden Cardiac Arrest in the General Population: Review of Traditional and Emerging Risk Factors. Canad J Cardiol. 2022;38(4):465-78.
6. 6. Osman J, Tan SC, Lee PY, Low TY, Jamal R. Sudden Cardiac Death (SCD) – risk stratification and prediction with molecular biomarkers. J Biomed Sci. 2019;26:39.
7. 7. Pan H, Hibino M, Kobeissi E, Aune D. Blood pressure, hypertension and the risk of sudden cardiac death: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2020;35(5):443-54.
8. 8. Faduyile F, Soyemi S, Sanni D, Wright K. Hypertension and Sudden Unexpected Deaths: An Autopsy Study of Four Hundred and Seventy-Seven Brought-in-Dead in a Tertiary Health Center. Niger Med J. 2019;60:13.
9. 9. NICE. Hypertension in adults: diagnosis and management. 2019. Available at: https://www.nice.org.uk/guidance/ng136. Accessed on 21 May 2026.
10. 10. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874.
11. 11. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-324.
12. 12. Shah SN, Munjal YP, Kamath SA, Wander GS, Mehta N, Mukherjee S, et al. Indian guidelines on hypertension-IV (2019). J Hum Hypertens. 2020;34(11):745-58.
13. 13. Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). The Lancet Diabetes Endocrinol. 2023;11(7):474-89.
14. 14. Ravindranath R, Sarma PS, Sivasankaran S, Thankappan KR, Jeemon P. Voices of care: unveiling patient journeys in primary care for hypertension and diabetes management in Kerala, India. Front Public Health. 2024;12.
15. 15. Sobierajski T, Surma S, Romańczyk M, Łabuzek K, Filipiak KJ, Oparil S. What Is or What Is Not a Risk Factor for Arterial Hypertension? Not Hamlet, but Medical Students Answer That Question. Int J Environ Res Public Health. 2022;19(13):8206.
16. 16. Meher M, Pradhan S, Pradhan SR. Risk factors associated with hypertension in young adults: a systematic review. Cureus 2023;15(4):e37467.
17. 17. Brown J, Yazdi F, Jodari-Karimi M, Owen JG, Reisin E. Obstructive Sleep Apnea and Hypertension: Updates to a Critical Relationship. Curr Hypertens Rep. 2022;24(6):173-84.
18. 18. Prenissl J, Manne-Goehler J, Jaacks LM, Prabhakaran D, Awasthi A, Bischops AC, et al. Hypertension screening, awareness, treatment, and control in India: A nationally representative cross-sectional study among individuals aged 15 to 49 years. PLoS Med. 2019;16(5):e1002801.
19. 19. Raina R, Khooblall A, Shah R, Vijayvargiya N, Khooblall P, Sharma B, et al. Cardiovascular implications in adolescent and young adult hypertension. Rev Cardiovasc Med. 2022;23(5):166.
20. 20. Lee J, Wilkens J, Meijer E, Sekher TV, Bloom DE, Hu P. Hypertension awareness, treatment, and control and their association with healthcare access in the middle-aged and older Indian population: A nationwide cohort study. PLoS Med. 2022;19(1):e1003855.
21. 21. Krishnamoorthy Y, Rajaa S, Sulgante S, Chinnakali P, Jaswal N, Goel S. Prevalence of hypertension and determinants of treatment-seeking behaviour among adolescents and young adults in India: an analysis of NFHS-4. J Public Health (Oxf). 2022;45(1):e48-56.
22. 22. Jadhav U, Solanki D, Kumar S, Hazra P, Alexander T, Gupta A, et al. Obesity and sympathetic overactivity in young individuals with hypertension: clinical perspective of Indian healthcare providers. Cureus. 2024;16(11):e74115.
23. 23. Julius S, Nesbitt S. Sympathetic overactivity in hypertension. A moving target. Am J Hypertens. 1996;9(11):113S-20S.
24. 24. Padmanabhan TNC, Dani S, Chopra VK, Guha S, Vasnawala H, Ammar R. Prevalence of sympathetic overactivity in hypertensive patients – A pan India, non-interventional, cross sectional study. Indian Heart J. 2014;66(6):686-90.
25. 25. Adua E. Decoding the mechanism of hypertension through multiomics profiling. J Hum Hypertens. 2023;37(4):253-64.
26. 26. Verdecchia P, Angeli F, Cavallini C, Aita A, Turturiello D, De Fano M, et al. Sudden Cardiac Death in Hypertensive Patients. Hypertension. 2019;73(5):1071-8.
27. 27. Tereshchenko LG, Soliman EZ, Davis BR, Oparil S. Risk stratification of sudden cardiac death in hypertension. Journal of Electrocardiology. 2017;50(6):798-801.
28. 28. McGorrian C, Yusuf S, Islam S, Jung H, Rangarajan S, Avezum A, et al. Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. Eur Heart J. 2011;32(5):581-9.
29. 29. Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, et al. Hypertension. Nat Rev Dis Primers. 2018;4:18014.
30. 30. Madhavan SR, Reddy S, Panuganti PK, Joshi R, Mallidi J, Raju K, et al. Epidemiology of Sudden Cardiac Death in Rural South India - Insights From The Andhra Pradesh Rural Health Initiative. Indian Pacing Electrophysiol J. 2011;11(4):93-102.
31. 31. Srivatsa UN, Swaminathan K, Sithy Athiya Munavarah K, Amsterdam E, Shantaraman K. Sudden cardiac death in South India: Incidence, risk factors and pathology. Indian Pacing Electrophysiol J. 2016;16(4):121-5.
32. 32. Rao BH, Sastry BKS, Chugh SS, Kalavakolanu S, Christopher J, Shangula D, et al. Contribution of sudden cardiac death to total mortality in India — A population based study. Int J Cardiol. 2012;154(2):163-7.
33. 33. Rao BH. Global burden of Sudden Cardiac Death and insights from India. Indian Heart J. 2014;66(Suppl 1):S18-23.
34. 34. Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Int Med. 2024;126:1-15.
35. 35. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-46.
36. 36. Shah SN, Munjal YP, Kamath SA, Wander GS, Mehta N, Mukherjee S, et al. Indian guidelines on hypertension-IV (2019). J Hum Hypertens. 2020;34(11):745-58.
37. 37. Poulter N. ARBs in hypertension. Br J Cardiol 2010;17:s6-9.
38. 38. DiPette DJ, Skeete J, Ridley E, Campbell NRC, Lopez‐Jaramillo P, Kishore SP, et al. Fixed‐dose combination pharmacologic therapy to improve hypertension control worldwide: Clinical perspective and policy implications. J Clin Hypertens (Greenwich). 2018;21(1):4-15.
39. 39. Jadhav U, Tiwaskar M, Khan A, Kalmath BC, Ponde CK, Sawhney J, et al. Hypertension in Young Adults in India: Perspectives and Therapeutic Options amongst Clinician’s in a Cross Sectional Observational Study. J Assoc Physicians India. 2021;69(11):11-2.
40. 40. Alexander T, Hiremath JS, Swahney JPS, Chandra S, Jain P, Chandra P, et al. Identifying Drug Prescription in Newly Diagnosed Hypertension Patients in India. J Clin Hypertens (Greenwich). 2025;27(1):e14963.
41. 41. Channaraya V, Marya RK, Somasundaram M, Mitra D, Tibrewala KD. Efficacy and tolerability of a β-1 selective β blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study. BMJ Open. 2012;2(3):e000683.
42. 42. Chen YD, Yang XC, Pham VN, Huang SA, Fu GS, Chen XP, et al. Resting heart rate control and prognosis in coronary artery disease patients with hypertension previously treated with bisoprolol: a sub-group analysis of the BISO-CAD study. Chin Med J (Engl). 2020;133(10):1155-65.
43. 43. Chopra HK, Sethi KK, Nair T, Ponde C, Ray S, Rao S, et al. National Consensus Statement on Role of Bisoprolol across Cardiovascular Continuum: Special Focus on Women. J Assoc Physicians India. 2025;73(5):e16-33.
44. 44. Feng Z, Zhang L, Wang Y, Guo H, Liu J. Efficacy and Safety of Bisoprolol in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. Int J Chron Obstruct Pulmon Dis. 2023;18:3067-83.
45. 45. Manjula S, Krishna Kumar M. Expert Opinion on the use of Bisoprolol-Telmisartan Combination in Indian Patients with Hypertension. Indian J 02 Cardio Biol Clin Sci. 2024;7(1):113.
46. 46. Wander GS, Panda JK, Pal J, Mathur G, Sahay R, Tiwaskar M, et al. Management of hypertension in patients with type 2 diabetes mellitus: Indian guideline 2024 by Association of Physicians of India and Indian College of Physicians. J Assoc Physicians India. 2024;72(8):e1-e25.